The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Phase I/II relapsed or refractory Hodgkin lymphoma studies demonstrate high rate of durable complete responses

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Two phase I/II trials that evaluated the safety and efficacy of CD30 CAR-T cell therapy in patients with relapsed/refractory Hodgkin lymphoma showed a high rate of durable complete responses and very favorable safety profile using autologous CD30 CAR-T cell therapy.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account